Greece - Buy the Di...
Health Care: Drugs
OncoGenex Pharmaceuticals Inc. (OGXI: NASDAQ)
$14.48 -0.89 | -5.79%
02/09/12 - 04:00 PM ET
97.06K / 40.70K
Vol / Avg. Vol:15.37 / 15.37
Open / Prev. Close:14.46 - 15.40
Today's Range:8.63 - 18.99
52 Wk Range:30.92%
Performance YTD:TheStreet Rating:
Portfolios with OGXI
- Portfolio NameUser Type
- Contributor10 Health-Care Stocks Outpe...
- Contributor9 Health Care Stocks With 1...
- Contributor10 Pharma Stocks With 100% ...
- Contributor10 Biotech Stocks Expected ...
- UserDouble QE2
- Contributor10 Stocks Expected to Doubl...
- Contributor10 Small-Cap Stocks With No...
- UserSUPRATRADE Top 10 Best-Rate...
- UserASCO 2010
- UserSolana Partners
Latest OGXI Headlines from TheStreet
- 10 Health-Care Stocks Outperforming the Index 06.07.11 | 01:06 pm
- 9 Health Care Stocks With 100% Buy Ratings 05.05.11 | 04:05 pm
- Biotech Stock Mailbag: Exact Sciences 02.25.11 | 07:02 am
- BIO CEO Conference Live Blog 02.14.11 | 02:02 pm
- 10 Biotech Stocks Expected to at Least Double 10.19.10 | 06:10 am
- 10 Stocks Expected to Double Amid QE2 10.11.10 | 08:10 am
- 10 Small-Cap Stocks With No 'Sell' Ratings 10.04.10 | 06:10 am
- OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 05.10.10 | 02:05 am
- OncoGenex Slammed on Teva Partnership: BioBuzz 12.21.09 | 10:12 am
- Teva, OncoGenex Sign Drug Development Deal 12.21.09 | 08:12 am
Press Releases for OGXI
- OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 02.07.12 | 08:02 am
- Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer - PR Newswire 02.02.12 | 08:02 am
- Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer - PR Newswire 02.02.12 | 08:02 am
- OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology - PR Newswire 01.04.12 | 08:01 am
- Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals - Business Wire 11.07.11 | 09:11 am
- OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer - PR Newswire 10.26.11 | 04:10 pm
- OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer - PR Newswire 10.20.11 | 04:10 pm
- OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011 - PR Newswire 10.18.11 | 04:10 pm
- OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial - PR Newswire 09.19.11 | 08:09 am
- OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference - PR Newswire 09.15.11 | 04:09 pm
Partner Headlines for OGXI
- Keeping An Eye On Isis - Seeking Alpha 01.13.12 | 07:01 pm
- Equity X factor often spells exasperation - Financial Times 12.10.10 | 11:12 pm
- Predictions for Biotech Data Heading to ASCO - Seeking Alpha 06.02.10 | 03:06 am
- Teva Expands Oncology Pipeline - Analyst Blog - Zacks 04.14.10 | 11:04 am
- Isis Loss Widens - Analyst Blog - Zacks 03.03.10 | 10:03 am
